Levetiracetam

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

左乙拉西坦（UCB L059）是一种新型抗惊厥化合物，对炎性疼痛具有抗痛觉过敏作用。

Levetiracetam(UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain.(In Vitro):Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity.Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 μM) treatment.MGMT expression is downregulated in GCSCs treated with Levetiracetam?(40 μg/mL)(In Vivo):Levetiracetam (10, 25, or 50?mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia.

——

Animal Model:Male Long-Evans ratsDosage:10, 25, or 50?mg/kg Administration:Intraperitoneal injection 60?min before hypoxia. Result:Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25?mg/kg and at 50?mg/kg. Anti convulsant activity was maximal at 50?mg/kg, at which HSs were reduced by 63.6%.

UCB L059

GPCR/G Protein

Calcium Channel

Calcium Channel| Synaptic vesicle glycoprotein 2A

Neurological Disease

——

102767-28-2

170.21

C8H14N2O2

>98% (HPLC)

Ethanol: 34 mg/mL (199.75 mM); Water: 34 mg/mL (199.75 mM); DMSO: 34 mg/mL (199.75 mM)

O=C(N)[C@H](CC)N1C(CCC1)=O

(S)-2-(2-oxopyrrolidin-1-yl)butanamide

(-20℃)

With Ice Pack

≥ 2 years